Novavax Inc
NASDAQ:NVAX
Intrinsic Value
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. [ Read More ]
The intrinsic value of one NVAX stock under the Base Case scenario is 8.32 USD. Compared to the current market price of 4.15 USD, Novavax Inc is Undervalued by 50%.
Valuation Backtest
Novavax Inc
Run backtest to discover the historical profit from buying and selling NVAX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Novavax Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 568.5m |
Receivables | 297.2m |
Other Current Assets | 278.1m |
Non-Current Assets | 653.6m |
PP&E | 491m |
Intangibles | 127.5m |
Other Non-Current Assets | 35.2m |
Current Liabilities | 1.6B |
Accounts Payable | 132.6m |
Accrued Liabilities | 394.7m |
Other Current Liabilities | 1.1B |
Non-Current Liabilities | 879.3m |
Long-Term Debt | 223.9m |
Other Non-Current Liabilities | 655.3m |
Earnings Waterfall
Novavax Inc
Revenue
|
983.7m
USD
|
Cost of Revenue
|
-343.3m
USD
|
Gross Profit
|
640.4m
USD
|
Operating Expenses
|
-1.2B
USD
|
Operating Income
|
-552.2m
USD
|
Other Expenses
|
7.1m
USD
|
Net Income
|
-545.1m
USD
|
Free Cash Flow Analysis
Novavax Inc
NVAX Profitability Score
Profitability Due Diligence
Novavax Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Novavax Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
NVAX Solvency Score
Solvency Due Diligence
Novavax Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Novavax Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVAX Price Targets Summary
Novavax Inc
According to Wall Street analysts, the average 1-year price target for NVAX is 15.71 USD with a low forecast of 4.04 USD and a high forecast of 39.9 USD.
Ownership
NVAX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NVAX Price
Novavax Inc
Average Annual Return | 573.52% |
Standard Deviation of Annual Returns | 1 229.51% |
Max Drawdown | -99% |
Market Capitalization | 578.9m USD |
Shares Outstanding | 139 952 992 |
Percentage of Shares Shorted | 36.57% |
NVAX News
Last Important Events
Novavax Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Novavax Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
Contact
IPO
Employees
Officers
The intrinsic value of one NVAX stock under the Base Case scenario is 8.32 USD.
Compared to the current market price of 4.15 USD, Novavax Inc is Undervalued by 50%.